Carboplatin PhaRes - Injection Carboplatin - 150mg/Vial 1 Injection(s) / Injection ZAS Corporation Introduction: Carboplatin PhaRes is used in the treatment of ovarian cancer and small cell lung cancer. It shows its working by stopping or slowing down the growth of cancer cells. Carboplatin PhaRes is given as an injection into veins under the supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very... Uses of Carboplatin PhaRes: Ovarian cancerSmall cell lung cancer Side effects of Carboplatin PhaRes: NauseaVomitingAnemia (low number of red blood cells)FatigueLow blood plateletsIncreased liver enzymesDecreased white blood cell count (neutrophils)Stomatitis (Inflammation of the mouth)Peripheral neuropathy (tingling and numbness of feet and hand)Diarrhea How to use Carboplatin PhaRes: Your doctor or nurse will give you this medicine. Kindly do not self administer. How Carboplatin PhaRes works: Carboplatin PhaRes is an anti-cancer medication. It works by damaging the genetic material (DNA and RNA) of the cancer cells which stops their growth and multiplication. What if you forget to take Carboplatin PhaRes?: If you miss a dose of Carboplatin PhaRes, please consult your doctor. Indication: Ovarian carcinoma, Lung cancer Administration: IV Preparation Single-dose lyophilized powder (reconstitution require) Reconstitute powder with sterile water for injection, D5W, or 0.9% NaCl to yield a final concentration of 10 mg/mL Can be further diluted to concentrations as low as 0.5 mg/mL with D5W or 0.9% NaCl Multidose premixed injectable solution Available as a 10 mg/mL aqueous solution Can be further diluted to concentrations as low as 0.5 mg/mL with D5W or 0.9% NaCl IV Administration Administer IV over 15 min or continuous IV infusion over 24 hr May also be administered intraperitoneally When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered... Adult Dose: Intravenous Small cell lung cancer; Advanced ovarian carcinoma Adult: IV As single agent in treatment-naive patients: 400 mg/m2; As single agent in previously treated patients: 360 mg/m2; W/ cyclophosphamide in treatment-naive patients: 300 mg/m2. Doses to be given not more frequently than every 4 wk. Adjust subsequent doses based on nadir of WBC and platelet counts. Hepatic Impairment Dose adjustment may not be necessary; not studied Child Dose: Solid tumor 300-600 mg/m² IV q4Weeks Sarcoma (bone/soft tissue) 400 mg/m²/day for 2 days every 21 days Brain tumor 175 mg/m² qWeek x 4 weeks with a 2 weeks recovery period between courses Bone marrow transplant preparative regimen 500 mg/m²/day x 3 days Retinoblastoma 1-2 mL subconjunctival injection of 10 mg/mL solution per dose Renal Dose: Renal impairment: CrCl (ml/min) >40 Recommended dose: 400 mg/m2. 20-39 Recommended dose: 250 mg/m2. Contraindication: Previous allergy; pregnancy, lactation; allergy to other platinum compounds; severe bone marrow depression; significant bleeding, aluminium containing needles and IV sets. Mode of Action: Carboplatin is an alkylating agent which binds covalently to DNA. It modifies the cell cycle by interfering with DNA structure and function. Precaution: Neonates; diminished renal function; neurotoxicity; liver function impairment. Lactation: not known if excreted in breast milk; do not nurse Side Effect: >10% Leukopenia (26-97%),Neutropenia (21-96%),Nausea (81-93%),Vomiting (81-93%),Anemia (14-90%),Magnesium loss (43-61%),Thrombocytopenia (33-66%),Alopecia (2-49%),Asthenia (11-41%),Elevated alkaline phosphatase (29-37%),Central neurotoxicity (5-26%),Elevated AST (19-20%),Peripheral neuropathy (6-15%) 1-10% Immune hypersensitivity reaction (2-9.2%),Elevated bilirubin (5%) Frequency Not Defined Visual disturbance (rare) Potentially Fatal: Bone marrow suppression and anaphylactic reactions. Pregnancy Category Note: Pregnancy Category: D Lactation: not known if excreted in breast milk; do not nurse Interaction: Increased risk of ototoxicity when used with aminoglycosides.